Claims for Patent: 8,071,556

Summary for Patent: 8,071,556

Title:	Peptide substance revealing a stress protective effect, pharmaceutical composition on its base, and the method of its application
Abstract:	Disclosed is a peptide glutamyl-aspartyl-glycine with general formula H-Glu-Asp-Gly-OH sequence 1 [SEQ ID NO:1], having a stress protective effect. Also disclosed is a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier. Also disclosed is a method of preventing or treating functional or stress induced disorders in a patient wherein the method involves administering an effective amount of the peptide to the patient.
Inventor(s):	Khavinson; Vladimir Khatskelevich (St. Petersburg, RU), Grigoriev; Evgeny Iosifovich (St. Petersburg, RU), Malinin; Vladimir Victorovich (St. Petersburg, RU), Ryzhak; Galina Anatolievna (St. Petersburg, RU)
Assignee:	Obschestvo S Ogranichennoi Otvetstevennostyu \"Sia Peptides\" (Saint-Petersburg, RU)
Application Number:	12/298,430
Patent Claims:	1. A pharmaceutical composition consisting of the peptide H-Glu-Asp-Gly-OH and a pharmaceutically acceptable carrier. 2. A pharmaceutical composition comprising the peptide H-Glu-Asp-Gly-OH and a pharmaceutically acceptable carrier, which is a parenteral or intranasal formulation. 3. A method of treating a patient for a stress induced disorder caused by osmotic stress, wherein the method consists of administering to the patient a pharmaceutical composition according to claim 1 having the peptide in a dose of 0.01-100 .mu.g/kg of body weight at least once a day during a period necessary for attaining a therapeutic effect in the patient. 4. The method according to claim 3, wherein the composition is administered parenterally or by intranasal infusion. 5. An intranasal formulation comprising the peptide H-Glu-Asp-Gly-OH and a pharmaceutically acceptable carrier. 6. The pharmaceutical composition of claim 1, which is a parenteral formulation. 7. The pharmaceutical composition of claim 1, which is an intranasal, formulation. 8. The pharmaceutical composition of claim 2, which is a parenteral formulation. 9. The pharmaceutical composition of claim 2, which is an intranasal formulation. 10. The pharmaceutical composition of claim 2, wherein the pharmaceutical carrier is physiological saline or sterile water. 11. A method of modulating the content of biogen amines in the brain cortex and/or the blood serum of a patient in need thereof, which method consists of administering to the patient a pharmaceutical composition according to claim 1 having the peptide in a dose of 0.01-100 .mu.g/kg of body weight at least once a day during a period necessary for attaining a modulating effect on the content of biogen amines in the brain cortex and/or the blood serum of the patient. 12. A method of increasing the level of c-fos gene expression in the neuronal cells of a patient under stress due to motional restriction, which method consists of administering to the patient a pharmaceutical composition according to claim 1 having the peptide in a dose of 0.01-100 .mu.g/kg of body weight at least once a day during a period necessary for attaining an increase in the level of c-fos gene expression in the neuronal cells of the patient. 13. A method of reducing the level of an enkephalinase in the serum of a patient in need thereof, which method consists of administering to the patient a pharmaceutical composition according to claim 1 having the peptide in a dose of 0.01-100 .mu.g/kg of body weight at least once a day during a period necessary for attaining a reduced level of an enkephalinase in the serum of the patient. 14. A method of treating a patient for hypoxic hypoxia, which method consists of administering to the patient a pharmaceutical composition according to claim 1 having the peptide in a dose of 0.01-100 .mu.g/kg of body weight at least once a day during a period necessary for reducing the hypoxic hypoxia in the patient.

Details for Patent 8,071,556

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2026-05-23